As Turkey pursues son fight against COVID-19[femalewith[femininewithrising number of vaccinations, an expert pointed out that the country has reached a stable level phase in the struggle.
“Due to the omicron variant, the case numbers went upmostly in the United States and Europe … to reach a stable course later and to decrease after that phase. As Turkey, we are in the stable phase now”, associated professor Afşin Emre Kayıpmaz told Ihlas News Agency (IHA) on Sunday.
Kayipmaz, also a member of the Ministry of Health’s Coronavirus Scientific Advisory Board, stressed that vaccination is even more crucial given that the omicron variant is highly transmissible, and added this case is numbered worldwide first hit a peak, then leveled off and began to decline after this period. He pointed out that Turkey is on a stable path.
“Scientific studies have shown that the omicron variant is more contagious compared to previous variants, manifesting with record- a high number of cases,” he said.
“We need to highlight a fact here: As the omicron variant spreads to more peoplehe continues to threaten our senior citizens over age of 65 and people with chronic illnesses such as also remains a menace for people who haven’t received their vaccines and boosters,” Kayıpmaz pointed out.
“I can say that the majority of The COVID-19 patients we have in Ankara City Hospital are people who have not received vaccines or boosters.
Booster shots are crucial
Kayipmaz also said that alongside the country developed Turkovac vaccine, Pfizer-BioNTech and Chinese Sinovac vaccines are also in use in Turkey, and stressed that booster injections are crucial for protection against the deadly disease.
“Vaccines are the tool that protects us from serious illness and hospitalization, and they are the most important help should we never encounter this virus. This is why booster shots need to do”, the official addedpointing out that full vaccination helps prevent serious diseases, even in the case of breakthrough infection.
Emphasizing that wearing masks largely prevent the spread of the omicron variant, Kayıpmaz urged Turkish citizens to continue to respect the rules of hygiene and social distancing.
Molnupiravir joins arsenal
Kayipmaz also referred to the recent statement by Health Minister Fahrettin Koca announcement that the antiviral drug Molnupiravir has joined Turkey arsenal against COVID-19[FEMALE[FEMININE
say the drug is already in use in numerous countries like the United States and the United Kingdom, Kayıpmaz said that son ability to prevent serious illness in senior citizens and people with immune deficiencies are crucial.
“It’s a drug that helps strengthen our defenses against disease,” he said.
“But let’s not forget that preventive medicine comes firstso on should focus everything on a good vaccination, wearing masks, social distancing, hygiene and avoidance of adults crowds.”
Thursday, Koca announced that Turkey has started distributing Molnupiravir to senior citizens and people with immune deficiencies.
In a statement, the Coronavirus Scientific Advisory Board said the drug significantly increases the success rate in Treatment of covid19.
Professor Alper Şener, member of the Coronavirus Scientific Council, also recently said that the drug would be effective in remove virus impact on the body.
“I think it’s okay reduce the rate of hospitalization and intensive care required, especially in patients aged 65 and over and those with additional chronic diseases,” he said.
Şener told Anadolu Agency (AA) that he also mark it first the time that the country use locally produced drug against the deadly disease. The introduction of medication arrive at a time when Turkey is struggling with a new vague in the pandemic, aggravated by the fast- spread omicron variant.
sener also stated that molnupiravir would be administered to senior citizens and people with chronic diseases like Diabetes. The drug is primarily aimed at preventing the virus from taking up residence in the lungs, the part of the body it affects the most. He added that the drug would be administered twice per day during the five-day treatment. He noted that the doses are much lower than those of favipiravir, another widely used drug in the first days of the pandemic in Turkey, adding that this could mitigate peoplesworried about the antiviral drugs used against COVID-19[FEMALE[FEMININE
Developed by US pharmaceutical company Merck, molnupiravir is expected to boost drug sales in 2022 up at $6 billion, according to a financial company statement released Thursday. The company announced last year than drugs reduced hospitalizations and deaths by 30% based on on clinical tests on adults with high-risk The factors. It was approved as second at-home medical treatment for the virus by the United States Food and Drug Administration (FDA) on Dec. 23, a day after Pfizer’s Paxlovid got green light. Merck has so far delivered 1.4 million courses of Molnupiravir since son approval. The company plans to dispense 3.1 millions courses across the United States in the coming months, in in addition to providing 4 millions lessons at 25 countries this year, said CEO Rob Davis.
Turkey matters on his vaccination program and urged the public to get their booster shots in two doses of vaccines are considered insufficient for full protection against the infection. The number of the doses administered since January 2021 are around 145 millions whereas more over 57.61 millions people have received a first vaccine injection, while nearly 53 millions people received their two doses. However, the number of people who received three doses of vaccines remains at about 26.6 millions.
Turkey reported 80,454 new coronavirus cases on Saturday.
According to a table shared by the Ministry of Health, 278 people have lost their lives and 96,664 others have recovered from the disease over the past daytime.
In addition, no less than 462,252 virus tests have been carried out nationwide. in the past 24 hours.
Since December 2019, the virus has been wreaking havoc over 5.87 millions of lives in at least 192 countries and regions, with over 422.05 millions of cases reported worldwide, according to the American University Johns Hopkins.